NasdaqCM - Nasdaq Real Time Price USD

Genetic Technologies Limited (GENE)

2.3900

+0.0200

(+0.84%)

At close: 4:00 PM EDT

2.4000

+0.01

(+0.42%)

After hours: 4:47 PM EDT

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Comp

GlobeNewswire yesterday

GENE
+0.84%
GNTLF
Genetic Technologies Announces $2 Million Registered Direct Offering

MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinar

GlobeNewswire 5 days ago

GENE
+0.84%
GNTLF
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists,

GlobeNewswire 6 days ago

GENE
+0.84%
GNTLF
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key

GlobeNewswire 7 days ago

GENE
+0.84%
GNTLF
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this ...

ACCESSWIRE 11 days ago

GENE
+0.84%
GNTLF

BIVI
GTG to pilot GeneType in Breast Screen centers across the U.S.

MELBOURNE, Australia, April 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the company is establishing a clinical implementation study with breast imaging centers across New York, Miami and Houston. The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently

GlobeNewswire 12 days ago

GENE
+0.84%
GNTLF
EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce an innovative partnership between GTG, and Humanise Health launching a "Know Your Risk" event featuring the company’s unique Risk Assessment portfolio, to be held at The Langham, Pasadena, California on the 21st of May. This unique gathering is dedicated to empoweri

GlobeNewswire 15 days ago

GENE
+0.84%
GNTLF
Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market

MELBOURNE, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company’s new digital strategy, led by the company’s recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG’s social media platforms. The various analytical markers all showed uplifts, in some cases

GlobeNewswire 21 days ago

GENE
+0.84%
GNTLF
GTG Global Collaborations and Innovation Update

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groupsContinuous development of the geneType portfolioA deep pipeline of new unique and ground-breaking tests Strong Global Academi

GlobeNewswire 28 days ago

GENE
+0.84%
GNTLF
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will be a world first; including over 200

GlobeNewswire 29 days ago

GENE
+0.84%
GNTLF
One Genetic Technologies Insider Raised Stake By 20% In Previous Year

Looking at Genetic Technologies Limited's ( ASX:GTG ) insider transactions over the last year, we can see that insiders...

Simply Wall St. last month

GENE
+0.84%
GTG to launch U.S. Customer Digital Media Sales Campaign

MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company’s geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is

GlobeNewswire last month

GENE
+0.84%
GNTLF
Launching our most comprehensive test and expanding into new global markets

MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with its inventive strategy for early disease detection and personalized wellness is pleased to share Business update for the quarter ending 31 December 2023 (Q2 FY24). GENE's pioneering initiatives in genomics-based tests place it at the forefront of precision medicine. Leading the world in risk predictio

GlobeNewswire 2 months ago

GENE
+0.84%
GNTLF
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on July 17,

GlobeNewswire 3 months ago

GENE
+0.84%
GNTLF
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this ...

ACCESSWIRE 3 months ago

GENE
+0.84%
GNTLD

GNTLF
GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness

MELBOURNE, Australia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies (GTG) is proud to provide details of a series of recent transformative initiatives. Our commitment to advancing early detection of serious diseases through a revolutionary non-invasive saliva test has been recently showcased on several national Australian media channels. These segments highlight geneType's potential to shape the future of proactive health management. Precision Medicine Takes Flight at Gold Coast Private

GlobeNewswire 4 months ago

GENE
+0.84%
GNTLF
Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change

MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect: (i) a share consolidation of its ordinary shares (the “Shares”) of one (1) for one hundred (100) existing Shares (the “Local Consolidation”) and (ii) a change of ratio in the Company’s American Depositary Share (“ADS”) program, comprising a change in th

GlobeNewswire 4 months ago

GENE
+0.84%
GNTLF
Here's Why Shareholders May Want To Be Cautious With Increasing Genetic Technologies Limited's (ASX:GTG) CEO Pay Packet

Key Insights Genetic Technologies to hold its Annual General Meeting on 21st of November Total pay for CEO Simon...

Simply Wall St. 5 months ago

GENE
+0.84%
Gene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide an update on the company activities for the quarter ending 30 September 2023. Highlights: Partnership signed with the Gold Coast Private Hospital (a member of Healthscope), to establish a Precision Medicine Clinic at the hospital.GeneType Multi-Test

GlobeNewswire 5 months ago

GENE
+0.84%
GNTLF
GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test. Highlights: Pancreatic cancer has a very high mortality rate, approximately 76%1 of those diagnosed will die within 1 year. The five-year survival rate is

GlobeNewswire 6 months ago

GENE
+0.84%
GNTLF

Performance Overview

Return	GENE	S&P/ASX 200 [XJO]
YTD	-0.42%	+1.22%
1-Year	-56.94%	+4.82%
3-Year	-87.99%	+8.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genetic Technologies Limited (GENE)

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Genetic Technologies Announces $2 Million Registered Direct Offering

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GTG to pilot GeneType in Breast Screen centers across the U.S.

EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market

GTG Global Collaborations and Innovation Update

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

One Genetic Technologies Insider Raised Stake By 20% In Previous Year

GTG to launch U.S. Customer Digital Media Sales Campaign

Launching our most comprehensive test and expanding into new global markets

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness

Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change

Here's Why Shareholders May Want To Be Cautious With Increasing Genetic Technologies Limited's (ASX:GTG) CEO Pay Packet

Gene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial

GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment

Performance Overview